Reaction
Effusion reporting signals
As of the last recalculation, Effusion appears in 1,351 FAERS reports alongside 22 co-occurring drug terms. The strongest observed disproportionality signal is BISACODYL SUPPOSITORIES (PRR 21.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Bisacodyl Suppositories | 18 | 21.7 | 21.7 |
| Biscodyl | 18 | 21.5 | 21.5 |
| Bisacodyl | 18 | 20.0 | 20.0 |
| Standardized Senna Concentrate | 14 | 17.3 | 17.3 |
| Fondaparinux Sodium | 9 | 17.2 | 17.3 |
| Imatinib | 16 | 14.1 | 14.1 |
| Trimethoprim | 10 | 13.2 | 13.2 |
| Dasatinib | 22 | 9.3 | 9.3 |
| Dexamethasone Sodium Phosphate | 6 | 9.1 | 9.1 |
| Valsartan And Hydrochlorothiazide | 8 | 9.1 | 9.1 |
| Desoximetasone | 11 | 9.0 | 9.0 |
| Brinzolamide | 5 | 8.9 | 8.9 |
| Imatinib Mesylate | 14 | 7.8 | 7.8 |
| Bosutinib | 4 | 6.9 | 6.9 |
| Dabrafenib | 9 | 6.6 | 6.6 |
| Cortisone Acetate | 5 | 6.3 | 6.3 |
| Botulinum Toxin Type A | 5 | 6.2 | 6.2 |
| Brentuximab Vedotin | 4 | 6.0 | 6.0 |
| Lapatinib | 6 | 6.0 | 6.0 |
| Golimumab | 29 | 5.3 | 5.3 |
| Osimertinib | 7 | 3.4 | 3.4 |
| Ranitidine Hydrochloride | 10 | 2.8 | 2.8 |